Roche’s BTK inhibitor put on partial hold over concerns about potential liver injury

Roche’s fenebrutinib program in multiple sclerosis has been put on partial clinical hold over potential cases of drug-induced liver injury, the company said Thursday.

The BTK inhibitor class has been troubled by liver injury cases, with Merck KGaA’s evobrutinib in relapsing multiple sclerosis (RMS) and Sanofi’s tolebrutinib in multiple sclerosis…
Click here to view original post